STOCKS TELEGRAPH

Tag: Agile Therapeutics Inc.

  • AgileThought Inc: A Prominent Premarket Mover

    AgileThought Inc: A Prominent Premarket Mover

    AgileThought Inc., a global player in the digital transformation sector, has recently drawn significant attention in the premarket trading scenario.

    In the wee hours of the trading day, AgileThought Inc (AGIL) made substantial waves, becoming one of the key US stock premarket movers to watch.

    Recent Highlights

    Before delving deeper into the reasoning behind the heightened interest, it’s crucial to reflect on the company’s recent performance and announcements.

    AgileThought’s journey in the past few months has been marked by noteworthy progress, strategic decisions, and pivotal shifts.

    Q2 2023: A Mixed Bag

    In the second quarter of 2023, AgileThought (AGIL) reported a revenue of $38.3 million. While this marked a 17.0% YoY decrease and an 8.4% sequential drop, the company’s leadership remained optimistic.

    CEO Manuel Senderos highlighted the impact of market volatility and the decision to exit non-core revenues as key factors behind the dip.

    However, he expressed confidence in the company’s future, emphasizing the continuous efforts to build a robust pipeline and deliver top-tier services.

    Securing Additional Funding

    In late August 2023, AgileThought announced securing additional working capital funding, marking a significant step towards solidifying its financial foundation.

    The company also declared its decision to go private, backed by its senior secured lenders, Blue Torch Finance, LLC.

    This move is expected to reduce AgileThought’s debt load and infuse new capital into the business, setting the stage for a brighter and more efficient future.

    Restructuring and Chapter 11 Reorganization

    To facilitate this transition and protect all stakeholders, AgileThought decided to go through a Chapter 11 reorganization process under the U.S. Bankruptcy Code.

    This mechanism aims to allow the company to reorganize its finances efficiently, reduce its debt, and emerge with a healthier balance sheet.

    For this, AgileThought has entered an asset purchase agreement with affiliates of Blue Torch, subject to court approval and other customary conditions.

    AgileThought in the Premarket: A Closer Look

    In the premarket hours, AgileThought Inc (AGIL) emerged as a remarkable mover. The stock showed dynamic movement, with a premarket volume surge of 11.323 million shares. The closing price stood at $0.0844, indicating a positive change of $0.0015 or 1.81%.

    The premarket gap percentage of 4.22% and a price shift of +4.10% further underscored its remarkable activity.

    This resilience and potential highlighted by the premarket activities have positioned AgileThought as a company to watch closely. Investors and market watchers are keenly observing the stock’s performance and future trajectory.

    Conclusion

    In conclusion, AgileThought’s recent activities have stirred the waters in the premarket scene. As one of the prominent premarket movers, the company has shown significant promise amidst the market volatility.

    With its strategic decisions and restructuring plans, AgileThought is geared towards a future of enhanced service delivery and financial stability. As the market continues to watch, AgileThought Inc. is set to remain a noteworthy player in the premarket activity.

  • Update on Participation in Investor Events: Agile Therapeutics, Inc. (AGRX) Stock Rebounds After Hours.

    Agile Therapeutics, Inc. (AGRX) is focused on the fulfillment of women’s unmet health needs. It offers women contraceptive options and the preliminary product of the company is Twirla transdermal system.

    AGRX stock price in the regular trading on March 11, 2022, with a decrease of 6.58% was $0.26. Its price rebounded by 7.31% at the last check of the aftermarket session.

    AGRX: Events and Happenings

    On March 11, 2022, AGRX reported its Executive management to present at the following investor conferences.

    • Virtual Oppenheimer’s 32ndAnnual Healthcare Conference was held on March 17, and
    • Virtual Maxim Group and M-Vest 2022 Growth Conference held on March 28, 2022.

    On March 07, 2022, AGRX announced to issue its fourth-quarter 2021 financials on March 30, 2022. On January 12, 2022, AGRX acknowledged the issuance of guidelines by the tri-agencies, Department of Labor, Health and Human Services, and Treasury to aid in women’s accessibility to FDA-approved contraceptives. On January 10, 2022, AGRX informed the press about its collaboration with Afaxys Pharma, for the promotion of the Twirla transdermal system.

    AGRX: Key Financials

    On November 2, 2021, AGRX released its consolidated third-quarter 2021 financial report for the period ended September 30, 2021. Some important aspects are mentioned below.

    Revenue

    Net revenue delivered by the company in Q3 2021 was $1.3 million compared to no revenue in the same period of 2020. The company reported a 100% surge in its YoY net revenue. Also, it missed the revenue target by $175.2 thousand.

    EPS

    Net loss basic and diluted per share for the company during Q3 2021 was $16.8 million or $0.18 against $15.5 million or $0.18 in the same quarter of 2020. The company topped the EPS estimates by $0.01 and its net loss inclined YoY.

    Conclusion

    AGRX stock is down-performing as it hit 50% year-to-date as the pandemic-related economic restrictions are going to ease internationally. The company announced the upcoming presentation of its Executive management at the virtual investor’s conferences, resultantly its stock swelled. Also, the company is estimating $1.51 million revenue for Q4 2021 against -$0.15 EPS.

  • 15 Top Performing Stocks In Healthcare Industry

    15 Top Performing Stocks In Healthcare Industry

    The health care industry is considered to be the opportunity-rich industry. The demand in this industry is continuously increasing. Emerging technologies also play a very important role in the health care industry. Complex health and technology ecosystems and increasing consumer expectations are the major challenges which the health care industry is facing. Customers’ main priority is affordable and efficient drugs.

    If we look at the Drug manufacturers and specialty generic industry, this industry has seen a huge transformation over the last two decades. This industry is always striving to change fast enough to keep up with regulatory and patients needs. Currently, the healthcare industry has faced the major challenge of the COVID-19 pandemic. It is important to focus on what is happening in the market to increase industry growth.

    Here are the 15 leading companies in the Drug Manufacturers and specialty and generic industry:

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM)

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares were trading up 42.86% at $0.10 at the time of writing on Monday. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) share price went from a low point around $0.07 to briefly over $0.50 in past 52 weeks, though shares have since pulled back to $0.10. ZOM market cap has remained high, hitting $79.71M at the time of writing.

    Zomedica Pharmaceuticals Corp. has earlier revealed its proxy solicitor, Alliance Advisors, mailed the letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders. The virtual meeting is scheduled to hold on September 25, 2020.

    AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX)

    AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) last closed at $1.81, in a 52-week range of $0.70 to $2.68. AcelRx Pharmaceuticals Inc. (ACRX) announced today that the U.S. Army has granted AcelRx with an initial contract of up to approximately $3.6 million for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines. This company’s market capitalization has remained high, hitting $142.61 million at the time of writing.

    PPD Inc. (NASDAQ: PPD)

    PPD Inc. (NASDAQ: PPD) stock soar by 0.92% to $34.16. The most recent rating by KeyBanc Capital Markets, on June 04, 2020, is at an Overweight. PPD Inc. (PPD) has earlier revealed that it has received the honor of employer of choice around the world. PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. This company market capitalization has remained high, hitting $11.61 billion at the time of writing.

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) last closed at $0.80, in a 52-week range of $0.27 to $1.51. Analysts have a consensus price target of $1.25. Adamis Pharmaceuticals Corporation (ADMP) has earlier revealed the pricing of its previously announced underwritten public offering of 16,129,032 shares of its common stock at a public offering price of $0.62 per share, resulting in gross proceeds of approximately $10,000,000.

    Rockwell Medical Inc. (NASDAQ: RMTI)

    Rockwell Medical Inc. (NASDAQ: RMTI) last closed at $1.76, in a 52-week range of $1.10 to $3.85. Rockwell Medical Inc. (RMTI) has earlier named Russell L. Skibsted, M.B.A., as Executive Vice President, Chief Financial Officer  and Chief Business Officer (CBO), effective from September 15, 2020. This company market capitalization has remained high, hitting $96.44 million at the time of writing.

    TherapeuticsMD Inc. (NASDAQ: TXMD)

    TherapeuticsMD Inc. (NASDAQ: TXMD) stock soars 2.75% to $1.44. The most recent rating by Jefferies, on August 07, 2020, is at an Underperform. TherapeuticsMD Inc. (TXMD) Knight Therapeutics Inc. and TherapeuticsMD, Inc. revealed that they received the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. This company has a market capitalization of $368.06 million at the time of writing.

    Zoetis Inc. (NYSE: ZTS)

    Zoetis Inc. (NYSE: ZTS) rose 0.06% after gaining more than $0.01 on Tuesday. Zoetis Inc. (ZTS) has been recognized by Working Mother magazine for its career advancement opportunities, female representation and work-life programs. in the past 52-weeks of trading, Zoetis stock has fluctuated between the low of $90.14 and a high of $165.82. ZTS has moved up 78.59% from its 52-weeks low and moved down -2.92% from its 52-weeks high.  ZTS market cap has remained high, hitting $76.29 billion at the time of writing.

    DURECT Corporation (NASDAQ: DRRX)

    DURECT Corporation (NASDAQ: DRRX) stock drop by -5.41% to $1.75. The most recent rating by Oppenheimer, on July 31, 2020, is at an Outperform. DURECT Corporation (DRRX) has revealed the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. DURECT Corporation market cap has remained high, hitting $333.92 million at the time of writing.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) shares headed rising, higher as much as 0.56%. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Overweight. In the past 52-weeks of trading, this company stock has fluctuated between the low of $15.17 and a high of 32.66. Elanco Animal Health Incorporated (ELAN) has moved up 76.01% from its 52-weeks low and moved down -18.25% from its 52-weeks high.

    Guardion Health Sciences Inc. (NASDAQ: GHSI)

    Guardion Health Sciences Inc. (NASDAQ: GHSI) rose 1.22% on Monday. Guardion Health Sciences Inc. (GHSI) share price went from a low point around $0.17 to briefly over $0.95 in the past 52 weeks, though shares have since pulled back to $0.25. Guardion Health Sciences Inc.’s market cap has remained high, hitting $22.26 million at the time of writing.

    Agile Therapeutics Inc. (NASDAQ: AGRX)

    Agile Therapeutics Inc. (NASDAQ: AGRX) shares headed falling, lower as much as -6.89%. The most recent rating by Janney, on April 12, 2019, is at a Buy. In the past 52-weeks of trading, Agile Therapeutics Inc. stock has fluctuated between the low of $0.35 and a high of $4.77. Agile Therapeutics Inc. has moved up 807.14% from its 52-weeks low and moved down -33.37% from its 52-weeks high.

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) stock drops 0.02% after losing -0.01 on Tuesday. Momenta Pharmaceuticals Inc. (MNTA) share price went from a low point around $12.21 to briefly over $52.45 in the past 52 weeks, though shares have since pulled back to $52.36. Momenta Pharmaceuticals Inc.’s market cap has remained high, hitting $6.24 billion at the time of writing.

    Catalent Inc. (NYSE: CTLT)

    Catalent Inc. (NYSE: CTLT) stock drop 0.86% to $84.81. The most recent rating by Argus, on June 25, 2020, is at a Buy. In the past 52-weeks of trading, Catalent Inc. (CTLT) stock has fluctuated between the low of $31.04 and a high of $95.70. Catalent Inc. has moved up 173.23% from its 52-weeks low and moved down -11.38% from its 52-weeks high.  Catalent Inc. market cap has remained high, hitting $13.94 billion at the time of writing.

    Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD)

    Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) shares headed falling, lower as much as 2.22%. The most recent rating by Northland Capital, on June 17, 2020, is at an Outperform. Ironwood Pharmaceuticals Inc. (IRWD) share price went from a low point around $7.91 to briefly over $14.10 in the past 52 weeks, though shares have since pulled back to $9.48. Ironwood Pharmaceuticals Inc.’s market cap has remained high, hitting $1.54 billion at the time of writing.

    Athenex Inc. (NASDAQ: ATNX)

    Athenex Inc. (NASDAQ: ATNX) last closed at $12.80, in a 52-week range of $5.63 to $18.35. Athenex Inc. (ATNX) has moved up 127.35% from its 52-weeks low and moved down -30.25% from its 52-weeks high.  Athenex Inc. market cap has remained high, hitting $1.14 billion at the time of writing.

  • Here’s 15 Trending Stocks In Healthcare Industry To Watch

    Here’s 15 Trending Stocks In Healthcare Industry To Watch

    The global drug manufacturers specialty & generic industry continues to grow with the increase in the demand for medication. Efficient and inexpensive drugs are the main priority of customers. Drug manufacturing is more progressive with the advent of new technologies than other areas of the pharmaceutical industry. Companies are busy in acquisitions, collaborations to increase the specialty generic capacities.

    The development of cost-effective drugs and specialty generics is a complex process.  The drug generic market has seen a huge transformation over the last few decades. Its main competitive edge is the lower prices than branded drugs. The generic industry has experienced various changes as the coronavirus pandemic takes over the world. The purchase behaviors of customers also change in 2020.

    There are various companies which are fulfilling the needs of customers in the generic industry. Here are the top 15 best players in Drug manufacturers Specialty and Generic Industry:

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM)

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares were trading down -2.18% at $0.11 at the time of writing on Friday. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) share price went from a low point around $0.10 to briefly over $0.50 in past 52 weeks, though shares have since pulled back to $0.11.

    Zomedica Pharmaceuticals Corp. (ZOM) is scheduled to present at H.C. Wainwright Virtual Global Investment Conference on September 14, 2020. Zomedica has earlier partnered with Qorvo Biotechnologies to develop three new assays Cobalamin, Canine Pancreatic Lipase, and Folate to target the diagnosis of canine gastrointestinal issues. ZOM market cap has remained high, hitting $62.09M at the time of writing.

    Teva Pharmaceutical Industries Limited (NYSE: TEVA)

    Teva Pharmaceutical Industries Limited (NYSE: TEVA) last closed at $8.79, in a 52-week range of $6.25 to $13.76. Analysts have a consensus price target of $12.19. Teva Pharmaceutical Industries Limited (TEVA) affiliate Teva Neuroscience, Inc. earlier disclosed that new study data on AUSTEDO will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience. Teva market cap has remained high, hitting $9.79 billion at the time of writing.

    Mylan N.V. (NASDAQ: MYL)

    Mylan N.V. (NASDAQ:; MYL) stock soar by 1.79% to $15.33. The most recent rating by SVB Leerink, on January 27, 2020, is at an Mkt perform. Mylan N.V. (MYL) has earlier bought Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for €641.9 million. Mylan will pay the upfront payment of €263.2 million to Aspen. After generating cash from existing operations it will pay the €378.7 million on June 25, 2021. It has a market capitalization of $7.79 billion at the time of writing.

    Aurora Cannabis Inc. (NYSE: ACB)

    Aurora Cannabis Inc. (NYSE: ACB) last closed at $6.98, in a 52-week range of $5.30 to $78.00. Aurora Cannabis Inc. (ACB) has earlier appointed Miguel Martin its chief executive officer and also disclosed that it would book up to C$1.8 billion ($1.37 billion) in restructuring charges. It has a total market capitalization of $785.74 million at the time of writing.

    Bausch Health Companies Inc. (NYSE: BHC)

    Bausch Health Companies Inc. (NYSE: BHC) fall -1.60% after losing more than -$0.25 on Friday. Bausch Health Companies Inc. (BHC) has earlier shared its Inaugural Activity Report which showed the efforts of the Foundation from late 2017 through June 30, 2020.  Bausch Health Companies Inc. striving to improve the lives of patients globally. It has a total market cap of $5.58 billion at the time of writing.

    Endo International plc (NASDAQ: ENDP)

    Endo International plc (NASDAQ: ENDP) last closed at $2.80, in a 52-week range of $2.08 to $7.10. Endo International plc (ENDP) has earlier participated in the Citi 15th Annual BioPharma Virtual Conference being held on September 8-10, 2020. Endo International plc market cap has remained high, hitting $629.69 million at the time of writing.

    Sundial Growers Inc. (NASDAQ: SNDL)

    Sundial Growers Inc. (NASDAQ: SNDL) Shares headed falling, lower as much as -0.50%. The most recent rating by CIBC, on August 17, 2020, is at a Neutral. Sundial Growers Inc. (NASDAQ: SNDL) is scheduled to participate in
    Alliance Global Partners’ Consumer Cannabis Conference. Zachary George, Chief Executive Officer of Sundial, will take part in one-on-one sessions on September 29, 2020.

    Cronos Group Inc. (NASDAQ: CRON)

    Cronos Group Inc. (NASDAQ: CRON) fall -1.51% after losing more than -$0.08 on Friday. Cronos Group Inc. (NASDAQ: CRON) announced that its Board of Directors has named Kurt Schmidt President and Chief Executive Officer of the Company, effective September 9, 2020.  CRON also disclosed that Mike Gorenstein has been chosen as the Executive Chairman. Mike has worked as Chairman, President, and Chief Executive Officer of Cronos Group since 2016.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) last closed at $27.08, in a 52-week range of $15.17 to $32.66. Analysts have a consensus price target of $26.43. Elanco Animal Health Incorporated (NYSE: ELAN) is scheduled to participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020.  Elanco Animal Health Incorporated market cap remained high, hitting $10.86 billion at the time of writing.

    Agile Therapeutics Inc. (NASDAQ: AGRX)

    Agile Therapeutics Inc. (NASDAQ: AGRX) stock soar by 2.54% to $3.63. The most recent rating by Janney, on April 12, 2019, is at a Buy. Agile Therapeutics Inc. (AGRX) is scheduled to host a virtual investor/Analyst day on Monday, September 21, 2020. It has also introduced I’m So Done, an education and empowerment platform that encourages women to think about their current contraceptive method and decision-making journey.

    Mallinckrodt plc (NYSE: MNK)

    Mallinckrodt plc (NYSE: MNK) Shares headed falling, lower as much as -7.69%. The most recent rating by JP Morgan, on May 19, 2020, is at an Underweight. Mallinckrodt plc (MNK) share price went from a low point around $1.00 to briefly over $6.42 in the past 52 weeks, though shares have since pulled back to $1.20. Mallinckrodt plc market cap has remained high, hitting $110.00 million at the time of writing.

    HEXO Corp. (NYSE: HEXO)

    HEXO Corp. (NYSE: HEXO) fall -2.82% after losing more than -$0.02 on Friday. HEXO Corp. (HEXO) share price went from a low point around $0.35 to briefly over $4.62 in the past 52 weeks, though shares have since pulled back to $0.62. HEXO Corp. market cap has remained high, hitting $331.70 million at the time of writing

    Tilray Inc. (NASDAQ: TLRY)

    Tilray Inc. (NASDAQ: TLRY) stock drop by -5.68% to $5.31. The most recent rating by The Benchmark Company, on May 12, 2020, is at a Buy. Tilray Inc. (TLRY) stock fluctuated between the 52-weeks low range of $2.43 and a high range of $32.77. It has moved up 118.52% from its 52-weeks low and moved down -83.80% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.80. Its market capitalization is $716.00 million.

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) shares headed falling, lower as much as -0.12%. The most recent rating by Cowen, on August 03, 2020, is at an Outperform. Momenta Pharmaceuticals Inc. (MNTA)  share price went from a low point around $12.21 to briefly over $52.33 in the past 52 weeks, though shares have since pulled back to $52.08. Momenta Pharmaceuticals Inc. market cap has remained high, hitting $6.20 Billion at the time of writing

    Aphria Inc. (NASDAQ: APHA)

    Aphria Inc. (NASDAQ: APHA) stock drop by -2.81% to $4.50. The most recent rating by CIBC, on August 17, 2020, is at a Sector outperform. Aphria Inc. (APHA) stock fluctuated between the 52-weeks low range of $1.95 and a high range of $7.04. It has moved up 130.77% from its 52-weeks low and moved down -36.08% from its 52-weeks high. Its market capitalization is $1.20 Billion.